ABSTRACT SUBMISSION HAS NOW CLOSED. Please see guidelines below on how to submit a late-breaking abstract.

2019 Abstract Topics
Choose the most appropriate topic from the following:

Adaptive Immunity and Autoimmunity
Clinical Research and Epidemiology
Epidermal Structure and Function
Genetics and Cell Based Therapy
Innate Immunity and Inflammation
Melanoma and Other Skin Cancers
Photobiology and Pigmentation
Stem cells, Skin Appendages and Tissue Regeneration
Wound Healing and Tissue Remodeling

General Rules for Submission

Only one paper or poster may be presented by the same author at the meeting, although a presenter may be coauthor of any number of papers. The material should not have been published or presented at any European meeting prior to the date of presentation. It is permissible, however, to have presented the material previously at a regional meeting and to have had it published in abstract form in a publication associated with one of these meetings.

Abstract submissions may only be made through the website. Support is available by contacting the ESDR Office (office [at] esdr.org).

Abstract Destination

All abstracts submitted to the ESDR Meeting will be considered for oral presentation at the main ESDR meeting, except those marked for poster presentation by the author.

If your abstract is not selected for oral presentation at the main ESDR meeting, you may be invited to give an oral presentation at a satellite meeting of ESDR 2019. In this case you will be contacted directly by the organisers of the satellite meeting.

Abstract Publication

Abstracts will be published in the September 2019 issue of the Journal of Investigative Dermatology. Late-Breaking abstracts will not be published.

Submission Deadlne (CLOSED)

Monday 3 June 2019 at 09.00 (Central European Time).

Late-Breaking Abstracts

The ESDR is accepting late-breaking abstracts until 30 August 2019. Accepted abstracts will be shown as Electronic Posters only. Please send your submissions by email to office@esdr.org adhering to the general rules.

Abstract Submission – Detailed Instructions

Please complete the steps in the on-line abstract submission procedure on the ESDR abstract submission website adhering to the instructions given there. To submit the abstract text, you must copy your text into the form provided. Do not exceed 2300 characters (including spaces, authors and affiliations).

Abstracts must conform to the following standards:

Maximum of 10 co-authors.

Please indicate each co-author’s principal affiliation only.

DO NOT exceed 2300 characters including spaces (also including authors and affiliations). Overly long abstracts may be edited.

DO NOT use graphics or tables.

DO NOT use subheadings like “RESULTS, DISCUSSION” etc in your text. These will be deleted.

DO NOT number sections in your abstract.

DO NOT put author names or affiliations in the  abstract text. This will help to ensure that your abstract is reviewed fairly.

DO NOT use capitals or underline for emphasis in the text. Use the standard Symbol font for Greek and math symbols.

DO NOT mention support of work by a research grant.

DO NOT include references. These will be deleted.

The title must be brief and indicate clearly the nature of the investigation. The title should be upper and lowercase letters. Abbreviations must not be used in the title.

Nonproprietary (generic) names should be given the first time a drug is mentioned in the body of the abstract and should be written in small letters. The first letter of a proprietary name is always capitalized, e.g., cyproheptadine (Periactin).

The abstract body should be organised as follows:

(a) a sentence describing the purpose of the study;

(b) a statement of experimental design or method used;

(c) a summary of results, presented in sufficient detail to support the conclusion; and

(d) a statement of conclusions reached.

It is not satisfactory to state “The results will be discussed…” or “Other data will be presented.”

Failure to follow these instructions will result in a low priority score and may cause disqualification of your abstract.